Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Bluerock Therapeutics L.P. has 3 pending office actions in Biotechnology & Pharmaceuticals. The matters involve 3 distinct examiners and 3 distinct art units, indicating separate examination paths.
ZHU, JIANJIAN is the busiest examiner, with 1 pending matter. Matter-specific prior-art review and examiner analysis should guide response preparation.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (67%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ZHU, JIANJIAN | 1 | 58.1% | +82.5% |
| KELLY, TIMOTHY PATRICK | 1 | 77.8% | +17.1% |
| LEITH, NANCY J | 1 | 74.7% | +44.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18725451 | MEDICAL DEVICE SYSTEM AND METHOD FOR PREPARING A DOSE | KELLY, TIMOTHY PATRICK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19222083 | GENETICALLY MODIFIED CELLS FOR ENHANCED IMMUNE EVASION IN ALLOGENEIC CELLULAR THERAPIES | ZHU, JIANJIAN | 91d overdue |
| 18725451 | MEDICAL DEVICE SYSTEM AND METHOD FOR PREPARING A DOSE | KELLY, TIMOTHY PATRICK | — |
| 18551651 | METHODS FOR OBTAINING INDUCED PLURIPOTENT STEM CELLS | LEITH, NANCY J | — |
| Art Unit | Apps |
|---|---|
| 1631 | 1 |
| 3753 | 1 |
| 1653 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19222083 | GENETICALLY MODIFIED CELLS FOR ENHANCED IMMUNE EVASION IN ALLOGENEIC CELLULAR THERAPIES | ZHU, JIANJIAN | 1631 | §103 | Non-Final OA | 91d overdue | Pending | May 29, 2025 |
| 18725451 | MEDICAL DEVICE SYSTEM AND METHOD FOR PREPARING A DOSE | KELLY, TIMOTHY PATRICK | 3753 | §102§103§112 | Non-Final OA | — | Pending | Jun 28, 2024 |
| 18551651 | METHODS FOR OBTAINING INDUCED PLURIPOTENT STEM CELLS | LEITH, NANCY J | 1653 | §103Other | Non-Final OA | — | Pending | Sep 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBluerock Therapeutics L.P. has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Jianjian Zhu has the most, with 1 of Bluerock Therapeutics L.P.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
